Protocole Emerges From Stealth With $6M Seed Round Led by Rare Capital to Build the First Clinical-Grade Peptide Platform

Protocole, a modern peptide platform focused on clinical-grade access and personalized protocols, today announced its launch out of stealth alongside a $6 million seed round led by Rare Capital, co-founded by investor Rachel Schow.

Peptides have rapidly gained attention across longevity, performance, and metabolic health. But as demand accelerates, access remains fragmented across research-grade products, compounding pharmacies, and informal networks, raising growing concerns around safety, quality, and clinical oversight.

At the same time, increasing regulatory attention on peptides and compounding practices is reshaping how these therapies can be accessed and delivered. As oversight tightens and the grey market recedes, access is expected to shift toward regulated pharmacy channels, creating a need for infrastructure that can support safe, scalable, and clinically guided use.

Protocole was founded at this inflection point by Delphine Le Grand and Cindy Yan, who worked together in the longevity space and saw firsthand that demand for peptides was outpacing the infrastructure required to deliver them safely, consistently, and with proper clinical guidance.

Through its platform, members receive personalized peptide protocols based on health goals, access to licensed clinicians, and products fulfilled through regulated pharmacy partners. Members complete an intake and receive a tailored protocol with ongoing access to clinical guidance and follow-up. The company’s approach emphasizes quality control and ongoing monitoring, positioning peptides within a more structured, clinically guided model rather than a consumer supplement category.

Rather than offering individual compounds in isolation, Protocole structures its offering around goal-oriented protocols designed to support areas such as recovery, performance, and longevity.

“Peptides are at an inflection point,” said Delphine Le Grand, co-founder of Protocole. “What Cindy and I saw firsthand was that demand was accelerating far faster than the systems around quality, guidance, and access. As regulation catches up to the category, there’s a need for infrastructure that makes peptides safe, legible, and scalable.”

“As access to protocols expands, what will ultimately matter is how they’re experienced – how people understand, trust, and integrate them into their daily lives” said Cindy Yan. “Our focus is on building that experience directly into the product, so the process feels clear to engage with from the start.”

Since its initial launch, Protocole has amassed a waitlist of thousands through a network of members, practitioners, and referrals, with growth primarily driven through word-of-mouth.

The company will use the funding to expand its clinical infrastructure, deepen its protocol library, and invest in vertically integrated systems across prescribing, fulfillment, and member experience.